Filing Flows › Emmaus Life Sciences (EMMA) › Q1 2026 › vs Q1 2025
Emmaus Life Sciences (EMMA) Q1 2026 vs Q1 2025 (year over year)
Emmaus Life Sciences's revenue fell $424K (-18%) from $2.4M in Q1 2025 to $2.0M in Q1 2026. The biggest changes: Endari US −$679K (-33%); Endari International +$385K (+194%); Product and Service Other −$130K (-85%).
Emmaus Life Sciences, Q1 2026: revenue $2.0M (-18% year over year), operating margin -41.5%, net loss $3.3M, operating cash flow −$344K. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Endari US | $1.4M | $2.1M | −$679K | -33% |
| Endari International | $583K | $198K | $385K | +194% |
| Product and Service Other | $23K | $153K | −$130K | -85% |
| Revenue | $2.0M | $2.4M | −$424K | -18% |
| Net loss | $3.3M | $2.3M | $1.0M | +43% |
| Costs & expenses | $5.3M | $4.7M | $581K | +12% |
| Operating costs | $2.8M | $3.4M | −$581K | -17% |
| Interest & other, net | $2.5M | $1.3M | $1.2M | +86% |
| Income tax | $4K | $4K | $0 | 0% |
| Cost of revenue | $168K | $225K | −$57K | -25% |
| Research & development | $40K | $176K | −$136K | -77% |
| Sales & marketing | $747K | $646K | $101K | +16% |
| General & admin | $1.9M | $2.3M | −$489K | -21% |
| Operating cash sources | $3.3M | $2.3M | $1.0M | +43% |
| Depreciation | $15K | $5K | $10K | +200% |
| Share-based compensation | $1K | $10K | −$9K | -90% |
| Working capital & other | $3.0M | $2.6M | $381K | +15% |
| Cash used in operations | $344K | −$279K | $623K | — |
| Net loss absorbed | $3.3M | $2.3M | $1.0M | +43% |
Questions
How much did Emmaus Life Sciences's revenue grow year over year in Q1 2026?
Emmaus Life Sciences's revenue fell $424K (-18%) from $2.4M in Q1 2025 to $2.0M in Q1 2026.
What drove Emmaus Life Sciences's revenue change in Q1 2026?
Endari US −$679K (-33%); Endari International +$385K (+194%); Product and Service Other −$130K (-85%).